SGRY · Surgery Partners, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $118.20M | $138.70M | $120.90M | $102.20M | $104.00M | $97.10M |
| Total Operating Expenses | $2.92B | $2.77B | $2.42B | $2.19B | $1.92B | $1.68B |
| D&A | $176.00M | $152.60M | $118.10M | $114.80M | $98.80M | $94.80M |
| Operating Income | $389.50M | $348.80M | $328.00M | $345.20M | $302.20M | $183.00M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $18.00M | $134.60M | ($300.0K) | $23.30M | $10.50M | ($20.10M) |
| Net Income | ($77.90M) | ($168.10M) | ($11.90M) | ($54.60M) | ($70.90M) | ($116.10M) |
| EPS - Basic | ($0.61) | ($1.33) | ($0.09) | ($0.59) | ($3.19) | - |
| EPS - Diluted | ($0.61) | ($1.33) | ($0.09) | ($0.59) | ($3.19) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $239.90M | $269.50M | $195.90M | $282.90M | $389.90M | $317.90M |
| Accounts Receivable | $602.20M | $579.10M | $496.40M | $456.30M | $430.20M | $382.20M |
| Inventory | $96.60M | $88.40M | $75.20M | $71.40M | $61.10M | $56.40M |
| Accounts Payable | $208.70M | $208.70M | $171.80M | $151.60M | $124.90M | $100.20M |
| Current Assets | $1.15B | $1.12B | $895.00M | $921.00M | $946.10M | $801.50M |
| Total Assets | $8.12B | $7.89B | $6.88B | $6.68B | $6.12B | $5.41B |
| Current Liabilities | $615.50M | $624.40M | $523.00M | $493.40M | $536.80M | $556.80M |
| Long-term Debt | $3.74B | $3.40B | $2.80B | $2.63B | $2.96B | $2.88B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $1.71B | $1.79B | $1.99B | $2.00B | $1.09B | $115.60M |
| Retained Earnings | ($815.20M) | ($737.30M) | ($569.20M) | ($557.30M) | ($502.70M) | ($431.80M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $274.30M | $300.10M | $293.80M | $158.80M | $87.10M | $246.90M |
| Investing Cash Flow | ($246.60M) | ($488.50M) | ($225.60M) | ($307.90M) | ($331.70M) | ($88.40M) |
| Financing Cash Flow | ($57.30M) | $262.00M | ($155.20M) | $42.10M | $316.30M | $66.70M |
| CapEx | $78.70M | $90.40M | $88.80M | $80.60M | $57.60M | $42.90M |
| Free Cash Flow | $195.60M | $209.70M | $205.00M | $78.20M | $29.50M | $204.00M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | -2.51 | -1.25 | -17.23 | -1.43 | -0.42 | -1.76 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -1.0% | -2.1% | -0.2% | -0.8% | -1.2% | -2.1% |
| Return on equity | -4.5% | -9.4% | -0.6% | -2.7% | -6.5% | -100.4% |
| Return on invested capital | 5.6% | 5.3% | 5.4% | 5.9% | 5.9% | 4.8% |
| Liquidity | ||||||
| Current ratio | 1.87 | 1.79 | 1.71 | 1.87 | 1.76 | 1.44 |
| Quick ratio | 1.71 | 1.65 | 1.57 | 1.72 | 1.65 | 1.34 |
| Cash ratio | 0.39 | 0.43 | 0.37 | 0.57 | 0.73 | 0.57 |
| Leverage | ||||||
| Debt / Equity | 2.18 | 1.90 | 1.41 | 1.32 | 2.72 | 24.89 |
| Debt / Assets | 0.46 | 0.43 | 0.41 | 0.39 | 0.48 | 0.53 |
| Debt / EBITDA | 6.61 | 6.79 | 6.29 | 5.73 | 7.38 | 10.36 |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 4.74 | 4.41 | 3.46 | 3.34 | 5.62 | 46.83 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.1x | 1.5x | 2.0x | 1.3x | 2.4x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | 9.7x | 11.6x | 14.9x | 10.7x | 12.9x | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.7% | 6.3% | -5.0% | 14.2% | 65.1% | -22.4% |
| Net income growth (YoY) | 53.7% | -1312.6% | 78.2% | 23.0% | 38.9% | -55.2% |
| EPS growth (YoY) | 54.1% | -1377.8% | 84.7% | 81.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -6.7% | 2.3% | 162.1% | 165.1% | -85.5% | 264.9% |
| FCF CAGR (5y) | -0.8% | 30.3% | 14.4% | - | -19.3% | 35.3% |
| Book value growth (YoY) | -4.3% | -9.9% | -0.6% | 83.5% | 842.0% | -61.1% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-General Medical & Surgical Hospitals, NEC
Comparing Surgery Partners against the 5 most active filers in the same SIC group.